Nasdaq:US$9.23 (+0.47) | HKEX:HK$14.22 (+0.64) | AIM:£1.58 (+0.06)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 3 Jun 2014

ASCO 2014: A phase 1b study of VEGFR inhibitor fruquintinib in patients with pretreated advanced colorectal cancer